teal triangle graphic

Investigator Sponsored Studies

About Our ISS Program

Alkermes seeks to support research designed and conducted by independent clinicians and scientists through our Investigator Sponsored Studies (ISS) program.

The ISS program reviews study concept submissions related to the ISS Areas of Interest below on a rolling basis. Alkermes may occasionally announce a Request for Proposals (RFP) for research in clinical areas where gaps in data have been identified. Submission deadlines for any RFP topics will be announced on this site.

The ISS research Alkermes supports must be based in the United States and is typically conducted by experienced researchers who have an established history of successfully completing research with independent funding.

Alkermes can provide its marketed products to the ISS programs it supports. In addition, there may be financial support available.

If you intend to request only study drug from Alkermes and will be seeking funding from a different source, we strongly recommend you submit your request to Alkermes for review before submitting a funding request to any third party.

Click here to apply

ISS Areas of Interest

Substance Use Disorders

  • Improving treatment initiation and adherence in Alcohol Use Disorder (AUD)/Opioid Use Disorder (OUD)
  • Long-term treatment outcomes, including real-world data in AUD/OUD
  • Neurologic profile of early recovery in OUD, including but not limited to sleep, cognition and craving
  • Digital technologies for assessment of physiological parameters (e.g., wearables) and/or treatment access and outcomes (e.g., telehealth) in AUD/OUD
  • Implementing medication for AUD in healthcare systems


  • Reduction in social burden (e.g., family, treatment team) through use of long-acting injectables (LAIs)
  • Demonstration of LAI benefits in specific comorbidities of schizophrenia (e.g., persistent substance problems) or subpopulations (e.g., persons with schizophrenia over the age of 60)
  • Short-term and long-term economic and clinical outcomes of LAI treatment in schizophrenia using real-world data
  • Outcomes research on whether LAI use supports continuity of care in schizophrenia, utilizing telehealth or other innovative technology-based approaches     

ISS Submission Process

ISS concept submissions are reviewed by a cross-functional team of medical and scientific staff to consider patient safety, operational feasibility, scientific merit, and alignment with Alkermes research goals and needs.
Please note that Alkermes cannot guarantee support for any ISS submission. All decisions will be made at Alkermes’ sole discretion. ISS submissions are accepted on a rolling basis.
  • Requests must be submitted via the online portal by the clinician or scientist

  • All submissions should be in concept form

  • Full proposals might be requested after the initial review has been completed by the Alkermes ISS Committee

Email ISS manager   Apply now

teal triangle graphic

Other Research Grants

Early career investigators may also be interested in the Alkermes Pathways Research Awards®, our annual research grant program that is designed to support the next generation of researchers who are focused on schizophrenia, bipolar disorder, alcohol use disorder (AUD) or opioid use disorder (OUD.) The 2021 program is currently accepting applications. 

Learn about Pathways